Shigellosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Shigellosis is a bacterial infection caused by members of the genus Shigella, which belong to the tribe Escherichia in the family Enterobacteriaceae. The infection affects the digestive system and has two basic clinical presentations: watery diarrhea associated with vomiting, mild to moderate dehydration, and dysentery characterized by a small volume of bloody mucoid stools and abdominal pain. In untreated adults, the average duration of symptoms is seven days, and the organism is cultivated from stools for 30 days or longer. Shigella species are classified into four species: S dysenteriae, S. boydii, S flexneri and S sonnei. The hallmarks of shigellosis are the bacterial invasion of the colonic epithelium and inflammatory colitis, resulting in the characteristic sign of bacillary dysentery: scanty, unformed stools tinged with blood and mucus. The diagnosis of shigellosis is usually confirmed by the cultivation of the etiologic agent from stools and slide agglutination using commercially available, absorbed rabbit antisera.
·
Approximately 500,000 cases of shigellosis are
estimated to occur annually in the United States.
Thelansis’s “Shigellosis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Shigellosis treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Shigellosis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Shigellosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment